BD Innova™ Preanalytical Automation System Helps Improve Clinical Laboratory Efficiency
Sparks, MD -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the expansion of its product portfolio with the addition of the BD Innova™ Preanalytical Automated Microbiology Specimen Processor, which is designed to help increase laboratory efficiency and automate the modern microbiology laboratory.
By acquiring the Lab Systems division of Dynacon, a privately held corporation based in Ontario, Canada, BD adds innovative product platforms from a leader in preanalytical microbiology automation. These product platforms include the innovative InocuLAB and Innova platforms.
"Today's clinical microbiology laboratories face many challenges; chief among them are a shortage of laboratory professionals and an increase in workload," said Philippe Jacon, President, Diagnostic Systems, BD. "The addition of Dynacon's Lab Systems portfolio demonstrates BD's commitment to providing labs with the tools and products they need to enhance the quality of their tests results, improve turnaround times and make the most cost-effective use of their resources."
Clinical laboratories throughout North America and Europe have used the InocuLAB system routinely for nine years to successfully process more than 42 million specimens. The recently launched Innova System, a versatile, state-of-the-art, high-throughput specimen processor, helps address laboratories' increasing needs for preanalytical specimen processing automation due to labor shortages or increasing test volumes. It also helps reduce laboratory errors associated with specimen handling. With best-in-class flexibility, the BD Innova System accommodates the full range of microbiology specimen containers, streak patterns, protocols and workflows.
"The features and benefits of Dynacon's Innova and InocuLAB platforms complement perfectly the capabilities of BD's innovative product portfolio," said Dr. Peter Hughes, Chairman, Director and Chief Executive Officer, Dynacon. "As a leader in infectious disease testing known for quality and reliability, BD is the right company to bring these successful platforms to more laboratories that need and demand reliable, high-performance, automated instruments."
For more information, please visit www.bd.com/ds/BDInnova.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
